SAN FRANCISCO, CA, AusperBio Therapeutics, a privately held clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies, has raised a $73M Series B funding.
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies to achieve a functional cure for chronic hepatitis B (CHB), today announced the successful completion of a USD 73 million Series B financing.
The round was led by HanKang Capital, with participation from Sherpa Capital, CDH Investments, and a strategic investor, as well as continued participation from existing investors Qiming Venture Partners, InnoPinnacle Fund, and YuanBio Venture Capital. This financing followed the company’s…
Read Full Article at: VC News Daily
Discover more from FundingBlogger
Subscribe to get the latest posts sent to your email.